Https Www Americanpharmaceuticalreview Com 1315 News 614486 Merck To Acquire Investigational B Cell Depletion Therapy Cn201 From Curon Biopharmaceutical
WEB RAHWAY NJ-- Merck Prescribes for Success
Business Wire-- Merck
Third Acquisition in 2024 Marks Continued Growth
RAHWAY, N.J. (BUSINESS WIRE) Merck (NYSE: MRK), known as MSD outside of the United States and Canada, announced today the signing of a definitive agreement to acquire CN201, an investigational B-cell depletion therapy, from Shanghai-based biopharmaceutical company Curon Biopharmaceutical.
This acquisition is the third by Merck in 2024, further solidifying their position as a leader in the development of innovative therapies for the treatment of cancer and autoimmune diseases.
CN201 is a next-generation CD3xCD19 bispecific antibody that augments and diversifies Merck’s pipeline with potential applications in hematologic malignancies, including B-cell non-Hodgkin lymphoma.
As per the agreement, Merck will make an upfront payment of $850 million to Curon Biopharmaceutical, with additional payments of up to $440 million contingent upon the achievement of certain development milestones.
The acquisition is subject to customary closing conditions and regulatory approvals and is expected to be completed in the third quarter of 2024.
Yahoo Finance
Comments